Oscient Pharmaceuticals
Founded Year
1961Stage
PIPE | IPOTotal Raised
$13.05MMissing: Oscient Pharmaceuticals's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Oscient Pharmaceuticals's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Oscient Pharmaceuticals Patents
Oscient Pharmaceuticals has filed 15 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
12/30/2011 | 12/9/2014 | Molecular biology, Genetics, Virus families, Transcription factors, Biotechnology | Grant |
Application Date | 12/30/2011 |
|---|---|
Grant Date | 12/9/2014 |
Title | |
Related Topics | Molecular biology, Genetics, Virus families, Transcription factors, Biotechnology |
Status | Grant |
Latest Oscient Pharmaceuticals News
Dec 2, 2016
Advertisement Topics Track topics on Twitter Track topics that are important to you Printed From BioPortfolio.com Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 01:53 EST 2 Dec 2016 | BioPortfolio Reports Home » Topics » Alliances, mergers acquisitions and partnerships » Latest News » Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation since January 2007. Key Findings Provides intelligence on Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation and its subsidiaries since 2007. Information about key financial and legal advisors for Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation's financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Oscient Pharmaceuticals Corporation formerly known as Genome Therapeutics Corporation's growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Oscient Pharmaceuticals Frequently Asked Questions (FAQ)
When was Oscient Pharmaceuticals founded?
Oscient Pharmaceuticals was founded in 1961.
Where is Oscient Pharmaceuticals's headquarters?
Oscient Pharmaceuticals's headquarters is located at 1000 Winter Street, Waltham.
What is Oscient Pharmaceuticals's latest funding round?
Oscient Pharmaceuticals's latest funding round is PIPE.
How much did Oscient Pharmaceuticals raise?
Oscient Pharmaceuticals raised a total of $13.05M.
Who are the investors of Oscient Pharmaceuticals?
Investors of Oscient Pharmaceuticals include Domain Associates, Highbridge Capital Management, UBS, Alexandra Investment Management, Abingworth and 19 more.
Who are Oscient Pharmaceuticals's competitors?
Competitors of Oscient Pharmaceuticals include Affibody, Elusys Therapeutics, GangaGen, Sonexa Therapeutics, OraPharma and 12 more.
Compare Oscient Pharmaceuticals to Competitors
Athersys develops biotechnology-based therapeutics.
Emiliem operates as a biopharmaceutical company that is engaged in early oncology R&D. The company develops Molecular Targeted Therapeutics (MTTs) for oncology and other indications. MTTs are therapeutic agents that target biologically important processes central to the development and progression of cancer and other diseases. The company's clinical development strategy is focused on identifying patients most likely to respond to treatment and monitoring clinical outcome with specific biomarkers used as diagnostic assays.
Pulmotect is a biopharmaceutical company that develops products (host-directed/pathogen-agnostic) to reduce morbidity and mortality in patients at risk of severe respiratory diseases.
Chroma Therapeutics is a biotechnology company founded to exploit the potential of chromatin biology for cancer drug discovery. Chroma is focused on the identification of anti-cancer agents that combine the efficacy of cytotoxics with the tumour cell selectivity of modern targeted therapeutics. Based in Oxford, UK, Chroma is developing a pipeline of anti-cancer drugs.
RevDia is a provider of a therapeutic diagnostic testing platform. The company's diagnostic testing platform is designed to detect an active periodontal infection. Its technology is intended to measure elevated levels of slgA in saliva that is specific to Aa and Pg virulence proteins, an attribute displayed by bacteria when it becomes pathogenic during an active infection.
HealOr is a biopharmaceutical company committed to the development and commercialization of therapeutics impacting skin cells' properties for the purpose of treating various skin pathologies. HealOr has completed a safety and primary efficacy study of its lead drug HO/03/03 a topical drug for the treatment of diabetic foot ulcers and venous leg ulcers.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.